FDA ad comm favors Zevra’s Niemann-Pick drug

Off Biotech, biotechnology, Business, drug development, drug prices, Human Health, Life Sciences, Medicine, Pharma, research, Science and Research, The Readout

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Morning! Today, we discuss the maneuverings of two interesting women in biotech: Verily alum Amy Abernethy and 23andMe CEO Anne Wojcicki. Also, we explore the dangers of off-brand GLP-1s, and see FDA advisers vote in favor of a Niemann-Pick drug.

Read the rest…

Read Original Article: FDA ad comm favors Zevra’s Niemann-Pick drug »

About The Author